trial · primary record
Ruxolitinib
T-cell Prolymphocytic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 36 |
| Primary completion | 2031-01-31 |
| Primary endpoint | Safety and Adverse Events (AEs) |
| Registry ID | NCT07311746 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:21.299Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07311746
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ruxolitinib · approval
- Ruxolitinib · compound